Chirfi Guindo Biography and Net Worth

CMO of Merck & Co., Inc.

Chirfi Guindo is chief marketing officer for Merck. He is responsible for leading the development and implementation of the company’s long-term strategy for the Human Health portfolio spanning oncology, vaccines, pharmaceutical and pipeline products.

Prior to this role, Chirfi was executive vice president and head of global product strategy and commercialization at Biogen.

Before joining Biogen in 2017, Chirfi spent more than 25 years with Merck in positions of increasing responsibility in finance, sales, commercial and marketing. During his time with Merck, he led global marketing for Merck’s HIV portfolio, and also led the company’s Human Health businesses in Canada, the Netherlands and South Africa. Chirfi has been recognized for developing strong talent and forging innovative public-private partnerships that expand access to Merck medicines, while elevating the profile of Merck as a patient-focused company.

Chirfi is a graduate of Ecole Centrale de Paris (France) with a degree in engineering and has a master’s of Business Administration from New York University’s Stern School of Business.

What is Chirfi Guindo's net worth?: The estimated net worth of Chirfi Guindo is at least $8.31 million as of February 9th, 2026. Guindo owns 70,615 shares of Merck & Co., Inc. stock worth more than $8,309,267 as of February 9th. This net worth approximation does not reflect any other investments that Guindo may own. Learn More about Chirfi Guindo's net worth.
How do I contact Chirfi Guindo?: The corporate mailing address for Guindo and other Merck & Co., Inc. executives is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. Merck & Co., Inc. can also be reached via phone at (908) 740-4000 and via email at [email protected]. Learn More on Chirfi Guindo's contact information.
Has Chirfi Guindo been buying or selling shares of Merck & Co., Inc.?: During the last quarter, Chirfi Guindo has sold $3,621,700.00 of Merck & Co., Inc. stock. Most recently, Chirfi Guindo sold 10,000 shares of the business's stock in a transaction on Monday, February 9th. The shares were sold at an average price of $118.41, for a transaction totalling $1,184,100.00. Following the completion of the sale, the chief marketing officer now directly owns 70,615 shares of the company's stock, valued at $8,361,522.15. Learn More on Chirfi Guindo's trading history.
Who are Merck & Co., Inc.'s active insiders?: Merck & Co., Inc.'s insider roster includes Sanat Chattopadhyay (Insider), Frank Clyburn (EVP), Robert Davis (CFO), Richard Deluca (EVP), Cristal Downing (Insider), Kenneth Frazier (Insider), Julie Gerberding (EVP), Clark Golestani (EVP), Chirfi Guindo (CMO), Michael Holston (EVP), E III (SVP), Rita Karachun (VP), Dean Li (VP), Caroline Litchfield (CFO), Steven Mizell (EVP), Johannes Oosthuizen (Insider), Joseph Romanelli (Insider), Inge Thulin (Director), Ashley Watson (SVP), Wendell Weeks (Director), David Williams (Executive vice president, chief information & digital officer), and Jennifer Zachary (EVP). Learn More on Merck & Co., Inc.'s active insiders.
Are insiders buying or selling shares of Merck & Co., Inc.?: During the last year, insiders at the sold shares 12 times. They sold a total of 333,052 shares worth more than $39,354,502.05. The most recent insider tranaction occured on February, 9th when CMO Chirfi Guindo sold 10,000 shares worth more than $1,184,100.00. Insiders at Merck & Co., Inc. own 0.1% of the company. Learn More about insider trades at Merck & Co., Inc..
Information on this page was last updated on 2/9/2026.

Chirfi Guindo Insider Trading History at Merck & Co., Inc.

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/9/2026	Sell	10,000	$118.41	$1,184,100.00	70,615
2/5/2026	Sell	20,000	$121.88	$2,437,600.00	80,615

Chirfi Guindo Buying and Selling Activity at Merck & Co., Inc.

Merck & Co., Inc. Company Overview

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Today's Range

Now: $117.67

$116.98

$121.88

50 Day Range

MA: $106.89

$96.91

$121.92

2 Week Range

Now: $117.67

$73.31

$122.66

Volume

16,154,340 shs

Average Volume

13,365,909 shs

Market Capitalization

$292.06 billion

P/E Ratio

16.16

Dividend Yield

2.79%

Beta

0.28